ER Modulation May Overcome AI Resistance in ESR1-Mutant Breast Cancer
Hope S. Rugo, MD, FASCO, discusses the research being done to develop more effective therapies for patients with advanced hormone receptor–positive, HER2-negative breast cancer who harbor an ESR1 mutation.
Source: OncLive